In the last 10 years, monoclonal antibodies targeting programmed death protein‐1 (PD‐1) or its ligand (PD‐L1) have revolutionized the treatment of NSCLC and were considered standard care for advanced disease as first‐line or later therapy, supported by multiple large‐scale clinical trials. The gene discussed is CD274; the disease is non-small cell lung carcinoma.